Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.8, Iss.18, 2007-12, pp. : 3257-3264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasatinib: A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By McCormack Paul L. Keam Susan J.

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1771-1795

Adis International

Access to resources Recommend Favorite

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias

By Santos Fabio P S Cortes Jorge

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2381-2395

Informa Healthcare

Access to resources Recommend Favorite

Imatinib: In Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By Cross Sarah A. Lyseng-Williamson Katherine A.

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2645-2654

Adis International

Access to resources Recommend Favorite

Nilotinib: In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

By Garnock-Jones Karly P.

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1579-1590

Adis International

Access to resources Recommend Favorite

Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia: A Viewpoint by Joseph Brandwein

By Brandwein Joseph

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2655-2656

Adis International

Access to resources Recommend Favorite